Investigation of whether metformin can be used safely and effectively in patients with type 2 diabetes on haemodialysis
A short term study of safety and glycaemic outcomes in haemodialysis patients with type 2 diabetes treated with metformin
Dr Tilenka Thynne
6 participants
Apr 1, 2012
Interventional
Conditions
Summary
This is a study aiming to evaluate whether metformin, an antidiabetic medication, can be used safety and effectively in patients with type 2 diabetes who are receiving haemodialysis for their end stage kidney disease. The study runs over 4 weeks and 500mg of metformin (one tablet) will be given to participants after each dialysis session in weeks 2-4 of the study (9 times). We hypothesise that metformin can be safely used in patients with type 2 diabetes with end stage renal failure if dosed based on predicted drug clearance.
Eligibility
Inclusion Criteria5
- > 18 years
- Type 2 Diabetes
- Receiving haemodialysis 3 times a week for greater than 3 months
- Patients in which metformin would normally be used if they had normal renal function.
- Consent
Exclusion Criteria3
- (1)Any patients in whom metformin would not be used in the setting of normal renal function including: Moderate to severe heart failure, liver failure, alcohol abuse, major psychiatric disorder, acutely unwell or otherwise medically unstable.
- (2)Unable or unwilling to self monitor and record blood glucose levels via glucometer readings.
- (3)Inability to provide written informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Metformin dosed orally at 500mg within one hour post each haemodialysis session for 3 weeks (after 9 dialysis sessions)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000352808